Colorectal News and Research

RSS

African Americans face higher risk of colorectal cancer

African Americans are at significantly higher risk of developing colorectal cancer, and being diagnosed with the disease at a later stage, than other ethnic groups. That's the finding of a paper being presented at the annual meeting of the American College of Gastroenterology in San Diego.

26 Oct 2009

John Muir Health earns Network Cancer Program accreditation

John Muir Health’s Walnut Creek and Concord campuses have earned a three-year accreditation with commendation as a Network Cancer Program (NCP) from the American College of Surgeons Commission on Cancer (CoC), a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients. John Muir Health is one of only two hospitals in California and the only one in the San Francisco Bay Area to receive the recognition.

24 Oct 2009

2009 Inspiration Gala raises $1.27 million for BC Cancer Foundation

The 2009 Inspiration Gala raised $1.27 million for the BC Cancer Foundation and colorectal cancer research at the BC Cancer Agency last night, as nearly 400 guests dined and donated during the emotion-filled, sold-out event.

24 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

Exact Sciences to use Hologic's Invader chemistry for colorectal cancer screening

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has obtained a worldwide license from Hologic Inc. for that company’s Invader, Invader plus and real-time Invader detection chemistries for the field of colorectal cancer screening.

From Hologic, Inc. 21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Research study on EGFR and HER2 expressions in BTC

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.

19 Oct 2009

ADI and CeTeCancer collaborate for research project

Radient Pharmaceuticals Corporation, a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics, Inc. (ADI) with CeTeCancer -- a Chilean-based research laboratory -- to validate the effectiveness of Radient Pharmaceuticals' Onko-Sure™ in vitro diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

15 Oct 2009

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.

15 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

Virginia Health Information releases HMO quality and satisfaction reports

Virginia Health Information (VHI), a nonprofit health information company, reports HMO quality and satisfaction reports at www.vhi.org.

13 Oct 2009

Health plans efforts to improve health care access to patients facing language barrier recognized by NCQA

The National Committee for Quality Assurance (NCQA), with support from The California Endowment, has recognized five managed care plans for their innovative efforts to improve health care access and quality for consumers facing language and cultural barriers that frequently impede their access to life-prolonging care.

13 Oct 2009

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.

13 Oct 2009

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute.

13 Oct 2009

NiTi Surgical Solutions to showcase its investigational bowel anastomosis device at the 95th ACS Congress

NiTi™ Surgical Solutions, an innovative surgical device company, today announced that it will showcase its new, investigational bowel anastomosis device this week at the American College of Surgeons (ACS) 95th Annual Clinical Congress in Chicago, Illinois. The device, which will be marketed as BowelRing™, represents the company’s next advancement in its innovative BioDynamix™ Anastomosis Technology platform.

12 Oct 2009

Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Ethicon Endo-Surgery, Inc., today unveiled its broad portfolio of energy delivery devices at the 95th Annual Clinical Congress of the American College of Surgeons (ACS).

12 Oct 2009

Colorectal News and Research

African Americans face higher risk of colorectal cancer

John Muir Health earns Network Cancer Program accreditation

2009 Inspiration Gala raises $1.27 million for BC Cancer Foundation

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Celgene announces fiscal 2009 third-quarter results

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Exact Sciences to use Hologic's Invader chemistry for colorectal cancer screening

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Research study on EGFR and HER2 expressions in BTC

ADI and CeTeCancer collaborate for research project

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Older generation antibiotic for treating colon cancer

Virginia Health Information releases HMO quality and satisfaction reports

Health plans efforts to improve health care access to patients facing language barrier recognized by NCQA

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

NiTi Surgical Solutions to showcase its investigational bowel anastomosis device at the 95th ACS Congress

Ethicon Endo-Surgery launches energy delivery devices at the 95th ACS Annual Clinical Congress

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News